Low specificity of voltage-gated calcium channel antibodies in Lambert–Eaton myasthenic syndrome: a call for caution
暂无分享,去创建一个
[1] D. Richman,et al. 3,4‐diaminopyridine base effectively treats the weakness of Lambert‐Eaton myasthenia , 2018, Muscle & nerve.
[2] J. Probasco,et al. Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results , 2017, Journal of Neurology.
[3] B. Eymard,et al. Lambert–Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer , 2017, Journal of Neurology.
[4] M. Sharrock,et al. Paraneoplastic autoantibody panels: sensitivity and specificity, a retrospective cohort , 2017, The International journal of neuroscience.
[5] Luay Shayya,et al. Clinical utility of seropositive voltage-gated potassium channel–complex antibody , 2016, Neurology. Clinical practice.
[6] C. Klein,et al. P/Q‐ and N‐type calcium‐channel antibodies: Oncological, neurological, and serological accompaniments , 2016, Muscle & nerve.
[7] B. Schoser,et al. Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS , 2016, Muscle & nerve.
[8] Jeffrey A. Cohen,et al. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4‐diaminopyridine , 2016, Muscle & nerve.
[9] Yuebing Li,et al. Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center , 2015, Muscle & nerve.
[10] J. Verschuuren,et al. Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies , 2011, The Lancet Neurology.
[11] Y. Hatanaka,et al. 3,4‐Diaminopyridine is more effective than placebo in a randomized, double‐blind, cross‐over drug study in LEMS , 2009, Muscle & nerve.
[12] P. Wirtz,et al. Efficacy of 3,4‐Diaminopyridine and Pyridostigmine in the Treatment of Lambert–Eaton Myasthenic Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study , 2009, Clinical pharmacology and therapeutics.
[13] M. Tsujihata,et al. Seronegative Lambert-Eaton myasthenic syndrome , 2002, Neurology.
[14] D. Sanders,et al. Associations between circulating sex steroid hormones and cognition in normal elderly women , 2000, Neurology.
[15] Jacqueline Palace,et al. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome , 1997, Journal of the Neurological Sciences.
[16] P. O'Suilleabhain,et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. , 1995, The New England journal of medicine.
[17] A. Vincent,et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[18] A. Vincent,et al. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder , 1989, Trends in Neurosciences.
[19] J. Daube,et al. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. , 1989, The New England journal of medicine.
[20] N. Murray,et al. AUTOIMMUNE AETIOLOGY FOR MYASTHENIC (EATON-LAMBERT) SYNDROME , 1981, The Lancet.
[21] B. Eymard,et al. Erratum to: Lambert–Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer , 2017, Journal of Neurology.